Introduction
Alzheimer's disease (AD), an age-related neurodegenerative disorder, is typically characterized by death of neurons, accretion of neurofibrillary tangles containing hyperphosphorylated tau, and extracellular deposition of amyloid (Ab) plaques in the brain (Citron 2004a; Perl 2010) . According to the amyloid cascade hypothesis, overproduction of Ab peptide increases the formation of senile plaques, which in turn leads to synaptic dysfunction and neuro-degeneration (Citron 2004a; Perl 2010) . The primary molecular events following onset and pathogenesis of AD has suggested the major role of Ab-peptides in disease progression, particularly in brain regions involved in cognition and memory. Crucial to the early onset of Alzheimer's disease, b-secretase (b-site amyloid precursor protein cleaving enzyme 1, BACE1) contributes to the accretion of amyloid precursor protein (AbPP) products. Endoproteolysis of the transmembrane protein AbPP is mainly initiated by the action of b-and c-secretases (Tanzi and Bertram 2005) . Several studies have demonstrated that BACE1 levels are enhanced in the AD brain (Vasaar et al. 2009 ). Therefore, a popular yet challenging therapeutic target for AD is to decrease the accumulation of Ab. These advancements have led to the use of BACE1 inhibitors with a successful outcome through clinical trials (Yan and Vassar 2014) .
Ab Peptides is well recognized to have a critical role to play in AD progression (Selkoe and Schenk 2003; Walsh and Selkoe 2007) . Consequently led to the development of Ab-related treatment strategies to inhibit the successive cleavage of AbPP by b-and c-secretase, and thereby reduce the levels of Ab peptides. Subsequent studies targeted the competing a-secretase in addition to the b-and c-secretase to modulate Ab production, was viewed as a viable approach towards anti-amyloid therapy (Citron 2004a) .
Although, there are several approaches that deliver therapeutic molecules to the brain (Neuwelt et al. 2008) , the variable nature of pathogenesis of AD, and the efficacy of these molecules in treatment of the disease is unpredictable. Additionally, treatment of AD is challenging due to presence of the BBB comprising of endothelial cells lining, the inner lumen that divides the circulating blood from the central nervous system (CNS) (Hawkins and Davis 2005; Pardridge 2005) , precluding effective outcomes. Strategies involving reduction in the level of Ab peptides by targeting b-secretase have suggested that there are no adverse consequences of knocking down expression of this gene (Citron 2004b; Sankaranarayanan et al. 2008) . However, the decreased efficacy of many of the aforesaid strategies in part is attributed to lack of target reach, target specificity and toxicity, hindering further advancement in disease intervention.
Efforts towards delivery of drugs to the brain in the recent past have demonstrated the use of peptides and fusion proteins to deliver RNAi therapeutics to the CNS. However, the delivery of siRNA in vivo entails the usage of carrier molecules that are safe, biocompatible, physiologically stable and easy to administer. RNAi has been demonstrated as a powerful tool to inhibit cellular gene expression (Elbashir et al. 2001; Kim and Rossi 2007) . These studies enabled the development of peptides that facilitate binding of siRNA, and simultaneously foster targeting specific receptors (El-Andaloussi et al. 2007; Kumar et al. 2007 ) across the blood-brain barrier. A major deterrant that arose from these carriers is the presence of cationic charge that led to non-specific bio-distribution of heterogeneously formed particles (Fiedel et al. 1976; Schneider et al. 2012) . Towards this goal, we have engineered a recombinant protein that have potential to bring about specific and efficient gene silencing for cancer therapy in xenograft mouse models (Dar et al. 2015) . Association of these fusion proteins with siRNA through conformationspecific binding led to physiological stability and functionality of the complex upon systemic delivery. This is also supported by a recent proof-of-concept study, wherein TARBP-BTP an engineered fusion construct enabled efficient transport of siRNA across the BBB resulting in consequential knockdown of BACE1 in vivo (Haroon et al. 2016) . The study demonstrated delivery of siRNA mediated by engineered TARBP-BTP fusion protein that led to specific and significant knockdown of BACE1 in cortical and sub-cortical regions of the brain in both AbPP-PS1 and wild-type mice. In the current study, we extended it further in AbPP-PS1 mice with the objective of devising a treatment approach, where long-term administration of siRNA for BACE1 knockdown mediated by TARBP-BTP would serve as a reliable strategy to decrease load of amyloid plaques in AbPP-PS1 mice brain. Our data substantiates the approach and potential of TARBP-BTP as an efficient and promising platform to foster efficient RNAi by the delivery of BACE1 siRNA, as an inhibitor of a key enzyme implicated in AD pathology. The preliminary findings of the study have been presented on bioRxiv (www.biorxiv.org), the preprint server for biology (Mohamed et al. 2016) .
Materials and methods
Monoclonal Anti-Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH) antibody (MAB374) was purchased from Millipore. Anti Ab antibody (ab2539), Anti BACE1 antibody (ab108394), Goat Anti-Rabbit IgG H&L (ab181474) were procured from Abcam. Congo Red (234610) was obtained from Calbiochem. Ni Sepharose 6 Fast Flow was purchased from GE Healthcare. All other reagents used were of highest purity.
Animals
Both transgenic AbPP-PS1 and wild-type (control) mice were maintained at an ambient temperature of 24-25°C in sterile individually ventilated cage, and 12/12 h light/dark cycles with ad libitum food and water. All the experiments were conducted according to the guidelines of the Institute's Animal Ethics Committee (IAEC) vide approved project # IAEC 76A/2016.
Purification of TARBP-BTP
Recombinant protein, TARBP-BTP, was purified as described earlier (Haroon et al. 2016) . Briefly, the protein expressed in Escherichia coli BL21(DE3) was purified using Ni-NTA affinity chromatography under denaturing conditions using urea. Cells were lysed by sonication in a buffer containing 6 M urea, 50 mM sodium phosphate pH 7.4, 300 mM NaCl, 10 mM Tris and 1mM PMSF. The clarified supernatant was loaded onto Ni-NTA sepharose matrix column, and washed with 0.1 % Triton X-114 in lysis buffer at 4°C to remove bacterial endotoxins (Reichelt et al. 2006) . Column bound protein was refolded by gradually reducing urea concentration, and eluted using sodium phosphate buffer containing 300 mM imidazole (pH 7.4). The eluted protein was dialyzed against PBS (pH 7.4) overnight. TARBP-BTP:siRNA complex was prepared as described previously (Haroon et al. 2016) . Briefly, siRNA was gradually diluted in phosphate buffered saline (PBS), and then mixed slowly with an equal volume of TARBP-BTP taken at 5-fold-molar excess.
Experimental design with mice
The study was conducted in double transgenic AbPP-PS1 mice (8-9 month old). The complex TARBP-BTP:siRNA was freshly prepared and stored on ice for 15 min prior to injection to animals. The AbPP-PS1 mice were divided into two groups for administration of TARBP-BTP or TARBP-BTP:BACE1-siRNA. A third group, which is the age matched non-transgenic control mice, received normal saline. The complex was administered intravenously into mice via tail vein every 4th day for seven times in 28 days. Following treatment, the memory of mice was evaluated using Morris Water Maze (MWM) test as described in the next section. Animals were euthanized, and different tissues were dissected for quantification of Ab plaques, and histopathology analysis.
Morris water maze test
Following treatment described in the preceding section, mice were subjected to MWM test to evaluate their spatial learning and memory (Vorhees and Williams 2006) . In brief, MWM test was carried out in a circular tank (diameter 150 cm) that contain a fixed hidden platform underneath the water surface. The tank was virtually divided into 4 quadrants, and specific patterns were provided as cues on the wall of the tank. The movement path of mice was video recorded using a camera, and analyzed using Ethovision software. During training period (1st to 4th day), mice were allowed to explore for 90 s to find the platform by consecutively placing them in the 3 quadrants. During this period the escape latency i.e. the time taken to reach the platform was monitored. The memory test was carried out on the 7th and 8th day. For the first memory test on 7th day, mice were placed in the second quadrant, and the latency to reach the platform was recorded. For the second test (memory retention) on 8th day, the platform was removed, and the time spent by the mice in the 4th quadrant was monitored. For statistical analysis involving memory and memory retention, the values were compared to the vehicle alone (TARBP-BTP protein alone) control group.
Tissue preparation
At the end of the MWM test, blood was collected from retroorbital sinus, and animals were euthanized by cervical dislocation under anesthesia. The different organs including brain were rapidly dissected and washed in PBS. The brain was divided laterally into two halves. The first half was dissected to isolate different brain regions including cerebral cortex and hippocampus using a brain matrix, and snap frozen in liquid nitrogen. The other half was used for immunohistochemistry analysis. For histochemical analysis, the brain tissue was fixed in 4% PFA for 20 h, followed by transferring the tissues into 30% sucrose solution, and then frozen in Optimal Cutting Temperature compound (OCT) media, and cryosectioned to 20 lm slices. The slices were collected in PBS, mounted onto Fisher Probe-on Plus slides, and air-dried overnight. To eliminate handling errors, and to ensure consistent staining, sections from all three groups were mounted onto the same slide, and subjected to same staining and washing conditions. Parallel sections were subjected to both immunohistochemistry and Congo Red staining as described below.
Ab immunostaining
Antibody recognizing epitope consisting of amino acids 1-14 of Ab peptide was used in this study. Mounted cryosections were washed with PBS followed by permeabilization with 0.1% Tween 20. The sections were washed with PBS, and blocked with 5% serum in phosphate buffered saline with tween-20 (PBST). This was followed by incubation with primary antibody (1:200 dilution in PBST) overnight at 4°C, then washed thrice, and treated with secondary antibody at 4°C for 1 h. The slides were washed again, counterstained with Hoechst 33342, and mounted using vectashield mounting media. The images were acquired 109 magnification using Leica SP5 AOBS confocal microscope, and quantitated by NIH-ImageJ software.
Congo Red staining for amyloid plaques
Coronal brain sections of mice corresponding to various treatment groups were subjected to Congo Red staining to visualize amyloid plaques using the protocol described earlier (Wilcock et al. 2006) . Briefly, overnight air-dried brain section mounted on slides were hydrated, followed by treatment with 80% ethanol saturated with NaCl for 20 min. The slides were subsequently treated with 0.2% Congo red solution prepared in 80% ethanol saturated with NaCl solution. Prior to treatment, both solutions were rendered alkaline by the addition of 10 mM NaOH. After 30 min exposure to Congo Red solution, slides were washed in 95% and 100% ethanol, and cleared in xylene. The coverslips were mounted using DPX mountant, and imaged using Axioplan upright microscope (Zeiss). Two sections from each animal were subjected to both Congo Red and Ab immuno-staining. Congo Red-positive pixels were quantified in same sections on the same day to avoid variation in lamp temperature, illumination and exposure settings. Congo Red-positive amyloid plaques were quantitated using NIH-ImageJ software. The images were segmented by hue-saturation-brightness (HSB) method to differentiate background and the area of Congo Red-positive pixels (Wilcock et al. 2006 ).
Histopathology
Tissues were cryosectioned to 12 lm thickness, and subjected to Hematoxylin and Eosin staining. Briefly, sections were air dried for 15 min, and dipped in isopropanol solution for 10 min. The sections were washed in distilled water, and stained with Harris hematoxylin solution for 2 min in a dark place. Following washing with distilled water, slides were stained with eosin, and immediately washed in distilled water, and then dehydrated by treating successively with ethanol (50 to 100%). Finally, the slides were cleared in xylene, and mounted using DPX mountant, and visualized using Axioplan upright microscope (Zeiss).
Immunoblotting
Hippocampal region of the brains of mice was lysed using a handheld homogeniser in Radio Immunoprecipitation Assay buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 2 mM EDTA, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS) containing protease cocktail inhibitor. The lysate was clarified by centrifugation, and the supernatant was used for immunoblotting. The total protein content of the lysate was assessed by modified Lowry's method (Markwell et al. 1978) , and resolved on a SDS PAGE (12%) gel by loading 25 lg of protein per lane. Proteins were subsequently transferred onto nitrocellulose membrane, and probed with antibodies for BACE1 and GAPDH. Blots were treated with the corresponding secondary antibody tagged with HRP, and visualized using PierceÒ ECL Western Blotting Substrate (Thermo Scientific).
Statistical analysis
In order to cover the entire section in one field, we did not acquire high-resolution images. Unpaired, two tailed Student's t-test was performed for evaluating the significance of difference for MWM test, quantification of Ab load by immunostaining and Congo Red-based staining. P value less than 0.05 was considered statistically significant.
Results and discussion
RNA interference, a post transcriptional regulatory mechanism found in higher organisms, renders the possibility of precisely modifying disease related genes, and with design of suitable carriers of siRNA leads to target- Figure 1 . Schematic of the experimental timeline and workflow. AbPP-PS1 and wild-type control mice were treated with TARBP-BTP:BACE1-siRNA and normal saline, respectively, every 4th day for 28 days. Mice were subjected to memory assessment through MWM test followed by euthanasia for molecular analysis. specific knockdown. In an important work carried out earlier, lentiviral vectors expressing BACE1 siRNA upon stereotactic injection was shown to reduce the plaque levels and improve spatial learning and memory in APP mice (Singer et al. 2005) . Although BACE1 impacts many physiological functions (Barao et al. 2016 ) that include neuregulin-dependent myelin sheath formation of peripheral nerves, BACE1 null mutant mice exhibited minimal phenotypical abnormalities (Willem et al. 2006; Nishitomi et al. 2006) , which indicates the possibility of manipulating this gene for therapeutic purposes. It has also been established that BACE1 knockout rescued hippocampal memory deficits in AD mice (Ohno et al. 2004; Weber et al. 2017) . Together, these studies support BACE 1 as a viable therapeutic target for AD.
Reducing Ab production by targeting the implicated genes responsible for the pathophysiology of AD is a pragmatic approach. A promising approach to treat Alzheimer's disease is to block the secretase enzyme, which is responsible for the production of toxic Ab peptides through cleavage of AbPP. Inhibiting c-secretase has a positive effect in reducing Ab levels in the brain. Although it takes five genes to produce neurotoxic Ab by a proteolytic mechanism (Haass 2004) , inhibiting c-secretase has a positive effect in reducing Ab levels in the brain. The discovery of c-secretase activating protein (GSAP) that controls Ab production (He et al. 2010 ) suggests a promising approach through the use of GSAP inhibitors that can be developed to cross the blood-brain barrier. However, it is associated with off target complications as c-secretase has an important role in notch processing. In contrast, b-Secretase is considered as a safer target for AD, as it is not critical for the normal functioning of the brain. Variety of drugs from small molecules to designed antibodies targeting b-secretases have been tested (Atwal et al. 2011; Vassar 2014; Kennedy et al. 2016) . However, the lack of suitable carriers for intravenous delivery of siRNA, hinders the translational potential of this strategy. Noting the efficacy of TARBP-BTP from our earlier study, in this report, we evaluated the delivery efficacy in a long-term concept study in AbPP-PS1 mouse models of AD. These mice were genotyped using gene specific primers (AbPP and PS1) prior to treatment. The overall experimental strategy targeting BACE1 is shown in the schematic presented in figure 1. The complex, TARBP-BTP:BACE1-siRNA, was injected into mice via tail vein as described in methods. Two groups of AbPP-PS1 mice received either TARBP-BTP:BACE1-siRNA complex (vehicle:siRNA) as the treated group or TARBP-BTP (vehicle) as a control group. Based on our earlier gene knockdown studies and previously reported studies on the kinetics of siRNA mediated knockdown (Bartlett and Davis 2006) , a treatment strategy was employed, wherein the complex was injected every 4th day for a period of 28 days to keep the BACE1 mRNA and protein levels consistently low.
Following treatment, cognitive function was assessed by monitoring learning and memory of mice using MWM test. The escape latency of mice in all groups improved with training ( figure 2A) . Moreover, the escape latency of TARBP-BTP:BACE1-siRNA administered AbPP-PS1 mice was lower than vehicle-treated transgenic mice ( figure 2B ). In the memory test, none of the vehicle-treated AbPP-PS1 mice could locate the platform during the test time (90 s), while TARBP-BTP:BACE1-siRNA treated could reach the platform in 48.8±25.4 s (p=0.064). Additionally, in memory retention test, TARBP-BTP:BACE1-siRNA-treated AbPP-PS1 mice spent significantly more time (29.3±6.8 s) in the target quadrant when compared with vehicle treated AbPP-PS1 mice (6.7±4.8 s, figure 2C ). The results of both tests indicated improvement in the memory of TARBP-BTP:BACE1-siRNA treated AbPP-PS1 mice, suggesting that the delivery of BACE1-siRNA mediated by TARBP-BTP resulted in the reduction of BACE1 levels (Haroon et al. 2016) leading to considerable decreases in Ab plaque levels, improving cognitive functions in AD mice.
To assess whether the improvement in memory observed in the TARBP-BTP:BACE1-siRNA treated AbPP-PS1 mice is a direct consequence of reduction in Ab plaque, the plaque load was analyzed in brain tissues using immuno-histochemical approach. In this analysis, anti human Ab antibody was used since double transgenic mice harboring human AbPP gene with the Swedish mutation generates Ab aggregates that are recognized by the anti human Ab antibody (Jankowsky et al. 2004) . A marked reduction in the plaque load in the TARBP-BTP:BACE1-siRNA treated AbPP-PS1 mice was observed when compared with vehicle treated transgenic mice ( figure 3A ). In addition, Congo Red staining was use to quantify plaque load. The reduction in plaque load was further confirmed by Ab plaque staining with Congo Red, a dye that binds to the amyloid fibrils. Congo Red positive Ab plaques were lower in TARBP-BTP:BACE1-siRNA-treated AbPP-PS1 mice ( figure 4A;  supplementary figure 1 ). The analysis of Ab levels by both methods conclusively showed significantly lesser plaque load in the TARBP-BTP:BACE1-siRNA treated AbPP-PS1 mice when compared with vehicle-treated AbPP-PS1 mice (figures 3B, C and 4B, C). Additionally, the expression of BACE1 protein showed considerable reduction in TARBP-BTP:BACE1-siRNA-treated AbPP-PS1 mice when compared to vehicle alone ( figure 4C ). These results suggest that treatment of mice with BACE1-siRNA for a period of 28 days led to consistent reduction in BACE1 levels and thereby, a reduction in Ab plaque levels in TARBP-BTP:BACE1-siRNA treated AbPP-PS1 mice.
Safety and toxicity being prime attributes required of biomaterials, these aspects were earlier examined through cell-based assays (Haroon et al. 2016) , and found to be nontoxic even at high molar excess of the protein. In this study, aspects of toxicity were investigated by histopathological analysis of the major organs such as spleen, liver, kidney, heart and lungs of TARBP-BTP: BACE1 siRNA-treated mice. Interestingly, repeated dose of TARBP-BTP: BACE1-siRNA complex, did not result in any toxicity as revealed by absence of vascular changes or degeneration compared to control (figure 5). Moreover, there was no evidence of foci of necrosis or inflammation in these organs, which suggests the non-toxic nature of TARBP-BTP: BACE1-siRNA, offering scope for future investigations.
Our previous study indicated the beneficial impact of TARBP-BTP fusion protein that mediates target-specific delivery of therapeutic siRNA to brain tissues in AbPP-PS1 mouse model of AD (Haroon et al. 2016) , leading to a promising therapeutic approach towards anti-amyloid therapy. The present study clearly validates the potential of TARBP-BTP fusion protein as a delivery platform in delivering RNAi-based silencing of BACE1 gene for reducing the cleavage of AbPP protein, which reduces the load of Ab plaques in AD. It is evident that functional knockdown of BACE1 leads to significant reduction in Ab plaques in AbPP-PS1 mice. In future, other parameters such as dose escalation, dose response, usage of chemically modified siRNA for higher stability needs to be explored to unravel the full potential of the technique. Furthermore, the study illustrates the suitability of the carrier to facilitate basic neuroscience research by gaining a deeper understanding into the workings of the CNS in addition to addressing other neurological disorders as enumerated in this study. Importantly, the carrier enables synergistic delivery of a mixture of siRNAs to target key genes implicated in early onset of neurodegenerative disorders, an area of research that remains to be explored. The proof of concept study demonstrates TARBP-BTP fusion protein as a promising carrier for delivery of siRNA in potentially therapeutic quantities for AD intervention.
